Oppenheimer & Co. Inc. Purchases 1,636 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Oppenheimer & Co. Inc. raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 4.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 40,091 shares of the company’s stock after purchasing an additional 1,636 shares during the period. Oppenheimer & Co. Inc.’s holdings in Dyne Therapeutics were worth $1,440,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of DYN. Sei Investments Co. bought a new position in Dyne Therapeutics during the first quarter valued at approximately $693,000. Seven Eight Capital LP purchased a new position in shares of Dyne Therapeutics in the 1st quarter worth $516,000. Swiss National Bank grew its holdings in shares of Dyne Therapeutics by 41.5% in the first quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $2,419,000 after acquiring an additional 25,000 shares during the period. Mutual of America Capital Management LLC purchased a new stake in Dyne Therapeutics during the second quarter valued at $1,724,000. Finally, Vanguard Group Inc. lifted its holdings in Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after acquiring an additional 1,110,629 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insiders Place Their Bets

In other news, CEO John Cox purchased 32,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares of the company’s stock, valued at approximately $264,320. This trade represents a -133.33 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 158,975 shares of company stock valued at $5,693,789 over the last three months. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Price Performance

Shares of DYN opened at $28.39 on Monday. The firm has a market cap of $2.89 billion, a P/E ratio of -7.97 and a beta of 1.10. Dyne Therapeutics, Inc. has a 1 year low of $9.76 and a 1 year high of $47.45. The company has a 50 day simple moving average of $32.48 and a two-hundred day simple moving average of $35.24.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

DYN has been the subject of several research reports. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Guggenheim boosted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.